A new vaccine may one day delay the need to use ADT by harnessing patients’ immune systems, researchers reported at the 34th Annual Meeting & Preconference Programs of the Society for Immunotherapy of Cancer, or SITC 2019, which occurred in Maryland in November 2019.
